Using current techniques, Alzheimer’s disease, the most frequent cause of dementia, can only be detected once the typical plaques have formed in the brain. At this point, therapy seems no longer possible. However, the first changes caused by Alzheimer’s take place on the protein level up to 20 years sooner. A two-tier method developed at Ruhr-Universität Bochum (RUB) can help detect the disease at a much earlier stage. The researchers from Bochum published their report in the March 2019 edition of the journal “Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring”.
“This has paved the way for early-stage therapy approaches, where the as yet inefficient drugs on which we had pinned our hopes may prove effective,” says Professor Klaus Gerwert from the Department of Biophysics at RUB.
Protein folds incorrectly
In Alzheimer’s patients, the amyloid beta protein folds incorrectly due to pathological changes long before the first symptoms occur. A team of researchers headed by Klaus Gerwert successfully diagnosed this misfolding using a simple blood test; as a result, the disease can be detected approximately eight years before the first clinical symptoms occur. The test wasn’t suitable for clinical applications however: it did detect 71 per cent of Alzheimer’s cases in symptomless stages, but at the same time provided false positive diagnoses for nine per cent of the study participants. In order to increase the number of correctly identified Alzheimer’s cases and to reduce the number of false positive diagnoses, the researchers poured a lot of time and effort into optimising the test.
As a result, they have now introduced the two-tier diagnostic method. To this end, they use the original blood test to identify high-risk individuals. Subsequently, they add a dementia-specific biomarker, namely tau protein, to run further tests with those test participants whose Alzheimer’s diagnosis was positive in the first step. If both biomarkers show a positive result, there is a high likelihood of Alzheimer’s disease. “Through the combination of both analyses, 87 of 100 Alzheimer’s patients were correctly identified in our study,” summarises Klaus Gerwert. “And we reduced the number of false positive diagnoses in healthy subjects to 3 of 100. The second analysis is carried out in cerebrospinal fluid that is extracted from the spinal cord.
“Now, new clinical studies with test participants in very early stages of the disease can be launched,” points out Gerwert. He is hoping that the existing therapeutic antibodies will still have an effect. “Recently, two major promising studies have failed, especially Crenezumab and Aducanumab – not least because it had probably already been too late by the time therapy was taken up. The new test opens up a new therapy window.”
“Once amyloid plaques have formed, it seems that the disease can no longer be treated,” says Dr. Andreas Nabers, head of the research group and co-developer of the Alzheimer’s sensor. “If our attempts to arrest the progression of Alzheimer’s fail, it will put a lot of strain on our society.”
Sensor test is simple and robust
The blood test has been upgraded to a fully automated process at the RUB Department of Biophysics. “The sensor is easy to use, robust when it comes to fluctuation in concentration of biomarkers, and standardised,” explains Andreas Nabers. “We are now conducting in-depth research to detect the second biomarker, namely tau protein, in the blood, in order to supply a solely blood-based test in future,” concludes Klaus Gerwert.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Daily on Healthcare, presented by the Alzheimer’s Association: Presidential candidates weigh in on abortion in wake of bans on May 20, 2019 at 4:24 pm
Smart content. Deeper culture. Better access. Become a subscriber to the Washington Examiner magazine. SIGN UP! If you’d like to continue receiving the Washington Examiner's Daily on Healthcare ... […]
- Alzheimer's caregivers invited to free training conference on May 20, 2019 at 2:06 pm
FSU's program for Alzheimer's caregivers aims to reduce caregivers’ distress; improve their overall health; and enhance their skills. (Photo: ThitareeSarmkasat, Getty Images/iStockphoto) For too many ... […]
- Can Alzheimer’s Disease Be Prevented? on May 20, 2019 at 1:52 pm
A while back, I had a conversation with a few friends from high school about whether we’d want to know if we carried the genes that put us at a greater risk of developing Alzheimer’s disease. The ... […]
- Matters of the Mind: North Shore Residents Gather to Learn About How to Reduce the Risk of Developing Alzheimer’s disease on May 20, 2019 at 11:25 am
Illinois residents will gather on Wednesday, May 29 to learn ways to reduce their risk of developing Alzheimer's disease. Alzheimer's disease is the 6th leading cause of death in the United States and ... […]
- Medford family batting Alzheimer’s focused on living life to the fullest on May 20, 2019 at 10:13 am
At 51 years old, Medford resident Jeff Craddock never imagined he would ever have Alzheimer’s Disease. However, around one year ago completely "out of the blue," that’s exactly what he learned. “I can ... […]
- BioArctic Receives MEUR 15 Milestone Payment from Eisai for Start of BAN2401 Confirmatory Phase 3 Study in Early Alzheimer's Disease on May 20, 2019 at 9:03 am
STOCKHOLM, May 20, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company will receive a milestone payment of MEUR 15 from its partner Eisai for the ... […]
- What Causes Alzheimer’s Disease? on May 20, 2019 at 6:10 am
Alzheimer’s disease is a terrible neurological condition that is most often found in people over age sixty-five causing memory loss, mental deterioration, and eventually death. Alzheimer’s is ... […]
- Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression on May 20, 2019 at 2:20 am
The beta-site APP cleaving enzyme 1 (BACE1) is known primarily for its initial cleavage of the amyloid precursor protein (APP), which ultimately leads to the generation of Aβ peptides. Here, we ... […]
- A New Approach to Treating Alzheimer's Disease Receives Major NIA Backing on May 19, 2019 at 9:19 pm
T3D Therapeutics to Receive $9 Million Multiyear National Institute on Aging Grant for Phase 2 PIONEER Study in Mild-to-Moderate Alzheimer's Disease Patients RESEARCH TRIANGLE PARK, N.C., May 20 ... […]
- There won’t be a cure for Alzheimer’s disease in our lifetime on May 19, 2019 at 7:00 am
Biogen recently announced that it was abandoning its late stage drug for Alzheimer’s, aducanumab, causing investors to lose billions of dollars. They should not have been surprised. Not only have ... […]
via Bing News